Ohsu Knight Cancer Institute
- Country
- 🇺🇸United States
- Ownership
- Subsidiary
- Employees
- -
- Market Cap
- -
Calcitriol and Carboplatin in Treating Patients With Stage IV Prostate Cancer That Has Not Responded to Hormone Therapy
- Conditions
- Prostate Cancer
- First Posted Date
- 2004-01-08
- Last Posted Date
- 2017-04-28
- Lead Sponsor
- OHSU Knight Cancer Institute
- Target Recruit Count
- 19
- Registration Number
- NCT00017576
- Locations
- 🇺🇸
OHSU Knight Cancer Institute, Portland, Oregon, United States
Methotrexate, Cyclophosphamide, and Etoposide Phosphate Given With Osmotic Blood-Brain Barrier Disruption Plus Dexamethasone and Cytarabine in Treating Patients With Primary CNS Lymphoma
- Conditions
- Lymphoma
- First Posted Date
- 2003-12-11
- Last Posted Date
- 2017-04-21
- Lead Sponsor
- OHSU Knight Cancer Institute
- Target Recruit Count
- 22
- Registration Number
- NCT00074178
- Locations
- 🇺🇸
Oregon Health & Science University Cancer Institute, Portland, Oregon, United States
Treating Patients With Recurrent PCNSL With Carboplatin/BBBD and Adding Rituxan To The Treatment Regimen
- Conditions
- Drug/Agent Toxicity by Tissue/OrganBrain and Central Nervous System TumorsLymphomaThrombocytopenia
- Interventions
- First Posted Date
- 2003-12-11
- Last Posted Date
- 2023-07-06
- Lead Sponsor
- OHSU Knight Cancer Institute
- Target Recruit Count
- 17
- Registration Number
- NCT00074165
- Locations
- 🇺🇸
Good Samaritan Hospital Cancer Treatment Center, Hatton Institute, Cincinnati, Ohio, United States
🇺🇸Knight Cancer Institute at Oregon Health and Science University, Portland, Oregon, United States
Methotrexate, Procarbazine, Lomustine, Dexamethasone, and Cytarabine in Treating Patients With Primary CNS Lymphoma
- Conditions
- Lymphoma
- First Posted Date
- 2003-12-11
- Last Posted Date
- 2017-04-21
- Lead Sponsor
- OHSU Knight Cancer Institute
- Target Recruit Count
- 1
- Registration Number
- NCT00074191
- Locations
- 🇺🇸
Oregon Health & Science University Cancer Institute, Portland, Oregon, United States
Raloxifene With or Without Exercise Compared With Exercise Alone in Women Who Have Been Previously Treated for Breast Cancer
- Conditions
- Breast CancerMenopausal SymptomsOsteoporosis
- First Posted Date
- 2003-08-06
- Last Posted Date
- 2012-05-28
- Lead Sponsor
- OHSU Knight Cancer Institute
- Target Recruit Count
- 80
- Registration Number
- NCT00031811
- Locations
- 🇺🇸
OHSU Knight Cancer Institute, Portland, Oregon, United States
Arsenic Trioxide and Imatinib Mesylate in Treating Patients With Chronic Myelogenous Leukemia
- Conditions
- Leukemia
- First Posted Date
- 2003-01-28
- Last Posted Date
- 2012-05-28
- Lead Sponsor
- OHSU Knight Cancer Institute
- Target Recruit Count
- 16
- Registration Number
- NCT00053248
- Locations
- 🇺🇸
UCLA Department of Medicine, Division of Hematology/Oncology, Los Angeles, California, United States
🇺🇸OHSU Knight Cancer Institute, Portland, Oregon, United States
🇺🇸H. Lee Moffitt Cancer Center, Tampa, Florida, United States
Imatinib Mesylate Plus Cytarabine in Treating Patients With Chronic Myelogenous Leukemia
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2016-01-07
- Lead Sponsor
- OHSU Knight Cancer Institute
- Target Recruit Count
- 24
- Registration Number
- NCT00022490
- Locations
- 🇺🇸
Dana-Farber/Harvard Cancer Center at Dana Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸OHSU Knight Cancer Institute, Portland, Oregon, United States
Imatinib Mesylate and Interferon Alfa in Treating Patients With Chronic Myelogenous Leukemia
- Conditions
- Leukemia
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2012-08-20
- Lead Sponsor
- OHSU Knight Cancer Institute
- Target Recruit Count
- 25
- Registration Number
- NCT00015847
- Locations
- 🇺🇸
OHSU Knight Cancer Institute, Portland, Oregon, United States
🇺🇸Robert H. Lurie Comprehensive Cancer Center at Northwestern University, Chicago, Illinois, United States
Combination Chemotherapy Followed by Surgery in Treating Patients With Localized Prostate Cancer
- Conditions
- Prostate Cancer
- Interventions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2017-04-28
- Lead Sponsor
- OHSU Knight Cancer Institute
- Target Recruit Count
- 57
- Registration Number
- NCT00017563
- Locations
- 🇺🇸
OHSU Knight Cancer Institute, Portland, Oregon, United States
🇺🇸Portland VA Medical Center, Portland, Oregon, United States